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Abstract
Background: To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier,
pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore
offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and
histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome
levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in
various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging
due to nonspecific elevation in sera of patients with benign diseases. Here, we report for the first time differential,
disease-associated epigenetic profiles of intact cell-free nucleosomes (cfnucleosomes) containing specific DNA and
histone modifications as well as histone variants circulating in the blood. The study comprised serum samples from
59 individuals, including 25 patients with resectable pancreatic cancer, 10 patients with benign pancreatic disease,
and 24 healthy individuals using Nucleosomics®, a novel ELISA method.
Results: Multivariate analysis defined a panel of five serum cfnucleosome biomarkers that gave an area under the
curve (AUC) of 0.95 for the discrimination of pancreatic cancer from healthy controls, which was superior to the
diagnostic performance of the common pancreatic tumor biomarker, carbohydrate antigen 19-9 (CA 19-9) with an
AUC of 0.87. Combining CA 19-9 with a panel of four cfnucleosome biomarkers gave an AUC of 0.98 with an
overall sensitivity of 92 % at 90 % specificity.
Conclusions: The present study suggests that global epigenetic profiling of cfnucleosomes in serum using a simple
NuQ® immunoassay-based approach can provide novel diagnostic biomarkers in pancreatic cancer.
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Background
Pancreatic cancer has a 5-year survival rate of only 6 %
[1]. The poor prognosis is mainly due to the asymptom-
atic nature of its early stages, its aggressive biological be-
havior, and limitations of current detection technologies.
More than 80 % of the patients are inoperable at the
time of diagnosis. At present, the diagnosis of small,
early-stage tumors that can be surgically resected offers
patients the best chances for survival and can increase
5-year survival rates up to 30–40 % [2].
The standard serum marker for pancreatic cancer is
carbohydrate antigen 19-9 (CA 19-9). CA 19-9 is a
modified Lewis (a) blood group antigen. The sensitivity
of CA 19-9 for the diagnosis of pancreatic cancer is re-
ported as 79 % while the median specificity is 82 % [3].
According to the European Group on Tumor Markers
(EGTM) status report, CA 19-9 cannot be recommended
for screening purposes but only for monitoring response
to treatment in patients who had elevated levels prior to
treatment [4]. Therefore, there is an urgent need for new
and effective serum markers for the disease.
Apart from classical pancreatic cancer-associated sig-
naling pathways and genetic mutations [5], cancer cells
are also subject to epigenetic misregulation including
DNA methylation-mediated gene silencing and post-
translational modifications of histone proteins for
dynamic chromatin structural regulation [6]. The influ-
ences of these processes on the regulation of gene
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expression implicated in pancreatic cancer and oppor-
tunities for next-generation treatment were recently
reviewed [7]. Epigenetic alterations occur very early in
the transformation process, and these changes have been
proposed as biomarkers of transformation [8]. In
addition to gene-specific epigenetic markers, global
levels of epigenetic modifications also provide diagnostic
and prognostic information [9]. The importance of
epigenetic markers, including histone H3-specific post-
translational modifications, as prognostic factor in pan-
creatic cancer has been highlighted recently [10, 11].
Indeed, tumor-specific post-translational modifications
of histones influencing gene expression have been
identified in biopsy material, and the term “histone
onco-modifications” has been proposed for histone
modifications linked to cancer [8]. The blood of can-
cer patients contains cell-free DNA (cfDNA). While
the origins of cell-free DNA is subject to debate [12],
Mouliere et al. demonstrated that cfDNA in the blood
of cancer patients consists of small fragments cen-
tered around 166 bp [13]. This is consistent in size
with nucleosomal DNA (146 bp) and 20 bp linker
DNA protected as circulating cell-free nucleosomes
(cfnucleosomes).
Mono- and oligonucleosomes are released by chromatin
fragmentation during cell death. As a result, nucleosomes
are present in a range of diseases including inflammation,
infection, and benign diseases as well as cancer. As such,
the reported potential utility of circulating nucleosome
quantification has been limited to monitoring therapy effi-
cacy, including radio- and chemotherapy in pancreatic
cancer [14, 15] and relapse monitoring. However, circulat-
ing cfnucleosome measurements have not been used rou-
tinely in the clinic as it has not been previously possible to
detect tumor-specific, quantitative changes to circulating
cfnucleosome levels. Recently developed innovative
analytical techniques enabled detection of cfnucleosomes
containing histone and DNA modifications as well as
histone variants associated with tumor-specific epigenetic
changes, not only at the tumor site, but also in the circula-
tion [16–19].
We suggest that quantification of cancer-associated al-
terations in cell-free nucleosome-bound histone and
DNA modifications as well as histone variants could be
attractive to investigate as a diagnostic biomarker for
early detection of pancreatic cancer.
We report for the first time the diagnostic potential of
selected epigenetic profiles from circulating cfnucleo-
somes in pancreatic cancer using a simple immunoassay
profiling platform—Nucleosomics® (VolitionRx). In this
study, we examine and compare the specificity and sensi-
tivity of the cfnucleosome biomarkers and CA 19-9 serum
marker to distinguish pancreatic ductal adenocarcinoma
from benign pancreas disease and healthy controls.
Results
Study design
This prospective study consisted of 59 individuals and
comprised serum samples from patients with pancreatic
cancer (n = 25), benign pancreatic disease (n = 10), and
healthy controls (n = 24). As detection of late-stage pan-
creatic cancer is of little clinical value, all subjects
included in this study were selected from operable,
early-stage disease. All patients underwent pancreatic re-
section with curative intent, with 23 patients undergoing
pancreaticoduodenectomy and 2 patients undergoing
distal pancreatectomy. Histological differentiation in-
cluded well-differentiated in 1 patient, moderately differ-
entiated in 12 patients, and poorly differentiated in 12
patients. Median tumor size was 3.2 cm (0.3–8 cm).
Additional patient data are provided in Table 1.
Epigenetic profiling of circulating cfnucleosomes using
nucleosome assays
Epigenetic profiles of circulating cfnucleosomes of sub-
jects with pancreatic cancer, subjects with other pancreatic
conditions, and healthy control subjects were investigated
using ELISA-based NuQ® assays. Nine epigenetic features
of serum cell-free nucleosomes were measured, including
nucleosome-associated methylated DNA (5-methylcyto-
sine), histone modifications H2AK119Ub, H3K4Me2,
H3K9Me3, H3K27Me3, H3K9Ac, and H4Pan-acetylation
as well as histone sequence variants H2AZ and mH2A1.1,
using a novel, global epigenetic immunoassay approach.
The receiver operator characteristic (ROC) curves for
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each nucleosome assay in cancer vs. healthy or benign
and cancer vs. healthy groups are provided in Additional
file 1. The area under the curve (AUC) for the individual
ROC curves varied from 0.52 to 0.77 for cancer vs. healthy
and benign and 0.53–0.81 for cancer vs. healthy (Table 2).
Diagnostic sensitivity for individual nucleosome-based
biomarkers (at 90 % specificity) ranged from 0 to 40 %
for cancer vs. healthy and benign and from 0 to 60 % for
cancer vs. healthy (Table 2).
Multivariate analysis
The cumulative performance of cfnucleosome biomarkers
alone and in combination with CA 19-9 was evaluated
using multivariate analysis, optimized for AUC, for dis-
crimination of cancer vs. healthy and benign groups. Lin-
ear models, based on a weighted sum of one to five
variables (panel size limited to five to avoid overtraining)
were developed using Fisher’s linear discriminant (LDA)
and confirmed by logistic regression (LR) [20] (see the
“Methods” section below).
Model 1: −0.825 (5MC) − 2.909 (H2AZ) + 2.641
(H2A1.1) − 1.050 (H3K4Me2) − 0.551 (H2AK119Ub)
Model 2: −0.788 (5MC) − 2.338 (H2AZ) + 1.959
(H2A1.1) + 0.672 (H3K4Me2) + 0.782 (CA 19-9)
A box plot derived from the optimal panel of five as-
says (model 1) is shown in Fig. 1. The AUC for discrim-
ination of cancer vs. healthy and benign was 0.92, which
exceeded that of CA 19-9 with an AUC of 0.84 in our
cohort (Fig. 2). A box plot for a similar model (model 2),
in which the lowest weighted assay (nucleosome-associ-
ated H3K119Ub) in model 1 was replaced with CA 19-9,
is shown in Fig. 3. The AUC for discrimination of cancer
vs. healthy and benign groups increased to 0.94 (Fig. 2).
For discrimination of cancer vs. healthy groups, the five
cfnucleosome biomarker panel (model 1) had an AUC of
0.95 compared to 0.87 for CA 19-9. The four
Table 2 Nucleosome epigenetic feature, AUC, and sensitivity at
90 % specificity
NuQ® assay Cancer vs. healthy and
benign
Cancer vs. healthy
AUC Sensitivity (%) AUC Sensitivity (%)
H3K4Me2 0.52 0 0.53 0
mH2A1.1 0.58 16 0.64 40
H3K9(Ac) 0.61 12 0.69 44
H3K27Me3 0.64 40 0.68 40
H4Pan(Ac) 0.67 24 0.71 36
H2AZ 0.68 28 0.72 36
5-Methylcytosine (5MC) 0.70 40 0.72 40
H2AK119Ub 0.70 36 0.78 60
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Fig. 1 Discrimination of five NuQ® assay panel for pancreatic cancer,
benign disease, and healthy controls. Significant separation
(p < 0.001) between the pancreatic cancer (n = 25), the benign
samples (n = 10), and healthy controls (n = 24) was achieved with
pre-processed ELISA data from five nucleosomal biomarkers. A linear
model (Fisher’s linear discriminant) was used to generate a weighted
sum of values assigned as arbitrary units (AU) = −0.825 (5MC) − 2.909
(H2AZ) + 2.641 (H2A1.1) − 1.050 (H3K4Me2) − 0.551 (H2AK119Ub).
P value was determined by the Mann-Whitney U test. Box plots
indicate the median and 25th and 75th percentiles. Whiskers indicate
the 5th and 95th percentiles
1 - Specificity
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Fig. 2 ROC curve for discrimination of cancer vs. healthy and
benign. The area under the curve for an optimal panel of five
nucleosomal biomarkers (0.92) selected from a panel of nine was
significantly higher than that of CA 19-9 (0.85), the current gold
standard for pancreatic cancer. The AUC was further improved by
replacing the lowest weighted nucleosomal biomarker in model 1
with CA 19-9 in a panel with the four nucleosomal biomarkers (0.94)
to give a second, mixed biomarker, model
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cfnucleosome plus CA 19-9 biomarker panel (model 2)
increased the AUC to 0.98 (Fig. 4).
The sensitivities at 90 % specificity for discrimination
of cancer vs. healthy and benign as well as cancer vs.
healthy groups for the four and five cfnucleosome bio-
marker panels as well as the four cfnucleosome bio-
marker panel combined with CA 19-9 increased in line
with the AUCs (Table 3).
Discussion
To our knowledge, this is the first study describing the
epigenetic profiling of circulating cfnucleosomes for the
detection of pancreatic cancer. Our results suggest that
the levels and epigenetic profiles of cfnucleosomes in
serum differ in patients with cancer and in control pop-
ulations. Because epigenetic changes occur early in the
neoplastic transformation process, already in pre-
neoplastic stages, cfnucleosome profiles may represent
possible biomarkers for the early detection of cancer
[21]. Furthermore, the findings that global levels of epi-
genetic modifications in cfnucleosomes (as opposed to
gene-specific epigenetic profiling) could distinguish pan-
creatic cancer and benign cases strengthens their ability
to be used also in the differential diagnosis and over-
comes the previous challenge in separating patients with
cancer from benign organ-related diseases. The pancre-
atic cancer subjects included in this study all had oper-
able stage II disease, and these were detected with high
sensitivity.
Despite its current limitations, CA 19-9 is the gold stand-
ard to which all new investigational biomarkers are com-
pared. Our data show that while no single cfnucleosome
biomarker outperformed CA 19-9 (Additional file 1), these
markers can be combined to produce highly clinically sensi-
tive and specific biomarker panels that may also incorpor-
ate CA 19-9. A panel of five epigenetic features of
cfnucleosomes, identified from an initial screening panel of
nine, had a higher diagnostic accuracy than CA 19-9 in























Fig. 3 Discrimination of four NuQ® assay panel combined with CA
19-9 for pancreatic cancer, benign disease, and healthy controls.
Improved separation between the pancreatic cancer (n = 25), the
benign samples (n = 10), and healthy controls (n = 24) was achieved
with pre-processed ELISA data from four nucleosomal biomarkers
combined with CA 19-9. A linear model (Fisher’s linear discriminant)
was used to generate a weighted sum of values assigned as arbitrary
units (AU) = −0.788 (5MC) − 2.338 (H2AZ) + 1.959 (H2A1.1) + 0.672
(H3K4Me2) + 0.782 (CA 19-9). P value was determined by the
Mann-Whitney U test. Box plots indicate the median and 25th and
75th percentiles. Whiskers indicate the 5th and 95th percentiles
1 - Specificity
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Fig. 4 ROC curve for discrimination of cancer vs. healthy. The area
under the curve for an optimal panel of five nucleosomal
biomarkers (0.95) selected from a panel of nine was significantly
higher than that of CA 19-9 (0.87), the current gold standard for
pancreatic cancer. As for discrimination of cancer vs. healthy and
benign, the AUC was further improved by replacing the lowest
weighted nucleosomal biomarker in model 1 with CA 19-9 in a
panel with the four nucleosomal biomarkers (0.98) to give a second,
mixed biomarker, model
Table 3 Performance of cfnucleosome biomarker panels with and without CA 19-9
CA 19-9 4 NuQ® assays 5 NuQ® assays 4 NuQ® assays + CA 19-9
Clinical question AUC Sensitivity (%) AUC Sensitivity (%) AUC Sensitivity (%) AUC Sensitivity (%)
(90 % specificity) (90 % specificity) (90 % specificity) (90 % specificity)
Cancer vs. healthy 0.87 80 0.91 68 0.95 84 0.98 92
Cancer vs. healthy and benign 0.84 72 0.90 64 0.92 72 0.94 92
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21 of the 25 pancreatic cancer cases from healthy subjects
with two false positive results (sensitivity 84 % at 90 % spe-
cificity). Furthermore, the same test was able to distinguish
18 of the pancreatic cancer cases from subjects with other
pancreatic diseases or healthy controls with three false posi-
tive results (72 % sensitivity at 90 % specificity). There was
a single false positive from the healthy group and two in
the benign disease group including pre-cancerous intraduc-
tal papillary mucinous neoplasms (IPMN). This would
represent a potential screening sensitivity for cancer and
pre-cancerous disease of 74 %.
The markers tested were selected to represent a range
of histone isoform, histone modification, and methylated
DNA epigenetic signals rather than for suppressive or
activating function. The function of epigenetic marks
may differ when included at different loci and/or in rela-
tion to different genes [8]. Because the present study in-
volves the levels of epigenetic marks on global genome
level rather than a gene-specific level, it may be difficult
to specify function. In general, we have found that the
best discriminating makers in this study have a mixture
of functions. 5MC, H2AZ, and H2AK119Ub are thought
to be repressive in nature [22], H3K4Me2 is thought to
be associated with active genes [23], and mH2A1.1 is
thought to be associated with cell senescence [24]. From
this small sample of markers, it does not appear that one
could select discriminating markers on the basis of their
activating or suppressive nature.
Inclusion of CA 19-9 in a five-member ELISA panel
increased the clinical sensitivity for detection of pancre-
atic cancer to 92 % at 90 % specificity, both from healthy
subjects and from healthy and benign subjects. Only
three false positives were detected from the benign
group (none from the healthy group), including the same
IPMN case identified by the five nucleosomal biomarker
panel (model 1).
The main advantage of cfnucleosomes as biomarkers is
the rich variety of potential epigenetic features available,
which can allow fine-tuning of sensitivity and specificity.
Given the large pool of potential epigenetic features
present in nucleosomes, it is probable that alternative as-
says could generate improved panels. A practical advan-
tage of cfnucleosome biomarkers in this respect is that
they, like CA 19-9, are ELISA tests that can easily be per-
formed on a single small volume of serum.
When compared to other early detection strategies for
pancreatic cancer such as various imaging techniques
including endoscopic ultrasound (EUS), circulating cell-
free nucleosome assessment offers a potential non-
invasive approach to early pancreatic cancer detection.
Conclusions
In conclusion, our study provides the first evidence of the
diagnostic potential of cfnucleosome panels to detect
tumor-associated genome-wide epigenetic alterations in
serum for the non-invasive detection of pancreatic cancer.
Further studies with a broader range of assays in larger pa-
tient cohorts are warranted to evaluate the usefulness of




Study patients were undergoing treatment at the Depart-
ment of Surgery, Skåne University Hospital, Lund,
Sweden, between March 2012 and June 2014. Blood
samples were taken at diagnosis, prior to treatment.
Healthy control sera (n = 24) were obtained from donors
at the local blood donation center.
Serum samples were stored at −80 °C in the local bio-
bank until further use. The ethical approval for this study
was granted by the institutional review board at Lund
University with the approval number 2012/661. All sub-
jects gave written informed consent before taking part in
the study. Blood samples were collected in BD SST II
Advance tubes (serum separator tubes, 3.5 ml, product
no. 368498; Becton Dickinson, Franklin Lakes, NJ, USA).
The minimum clotting time was 30 min. The samples
were centrifuged at 2000×g at 25 °C for 10 min, and serum
was collected and stored in aliquots at −80 °C.
cfnucleosome immunoassays
Nine circulating cfnucleosome structures were measured
using NuQ® ELISAs (Belgian Volition SA, Namur,
Belgium) performed according to the manufacturer’s in-
structions, as reported previously [19]. The assays con-
sist of a single common method and reagent set which
employs a nucleosome capture antibody immobilized to
the solid phase in conjunction with nine separate detec-
tion antibodies directed to bind to the histone modifica-
tion or variant or DNA modification of interest (mouse
monoclonal antibody: anti-H3K4Me2, anti-H3K9Ac,
anti-H4Pan(Ac), anti-5MC, a rabbit monoclonal anti-
H2AK119Ub, rabbit polyclonal anti-mH2A1.1, anti-
H3K27Me3, anti-H2AZ, anti-H3K9Me3).
Briefly, serum samples (10 μl in duplicate) were diluted
with 50 μl 0.05 M Tris/HCl buffer pH 7.5 and incubated
overnight at 4–8 °C in 96-well microtiter plates coated
with a monoclonal anti-nucleosome antibody (Belgian
Volition SA, Namur, Belgium). After incubation, wells
were washed three times with 200 μl of 0.05 M Tris/HCl
buffer pH 7.5 containing 0.1 % Tween 20 (wash buffer)
and 50 μl of a biotinylated detection antibody, specific to
the epigenetic feature under investigation, was added.
Wells were incubated for 90 min at room temperature
and washed three times with 200 μl wash buffer, and 50 μl
of streptavidin-horseradish peroxidase (HRP = 0.25 μg/ml)
was added. After incubation for 30 min at room
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temperature, the wells were washed three times with
200 μl of wash buffer, and a peroxidase substrate—2,2′-
azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)—was
added. The optical densities of wells were read after
20 min with an X-Mark Microplate spectrophotometer
(BioRad).
Mean imprecision of sample duplicates in the nucleo-
some assays in this study ranged from 2 to 4 %. Intra-
and inter-plate imprecision for control samples was <4
and <6 %, respectively. In larger (27 plate) reproducibil-
ity studies (data not shown), intra- and inter-plate repro-
ducibility for nucleosome-associated 5-methylcytosine
analyses were 3 and 11 %, respectively. For nucleosome-
associated H3K9Me3 analyses, intra- and inter-plate
reproducibilities were 4 and 11 %, respectively.
Statistical analysis
Samples were assigned to three groups, healthy, cancer,
or benign. The data was pre-processed, taking the loga-
rithm to base 2 and dividing by the standard deviation
for each assay. Linear models were calculated using (1)
logistic regression (LR) and (2) Fisher’s linear discrimin-
ant (LDA) [20].
These determined the weighted sum of the NuQ® vari-
ables, assigned as arbitrary units (AU), that provided op-
timal discrimination between the cancer and combined
healthy and benign groups, identified as the optimal
clinical question (Fig. 5). A combination of nine individ-
ual NuQ® assays was included for selection (together
with or excluding CA 19-9 as a potential variable).
Models with one to five variables were ranked by area
under the receiver operator characteristic curve (AUC).
An upper limit of five variables was imposed to avoid
overtraining. Equivalent ROC curves were obtained from
LR and LDA. The analysis was conducted using the stat-
istical programming language R [25, 26].
Additional file
Additional file 1: Performance of individual nucleosome assays.
ROC curves for each nucleosome assay in cancer vs. healthy or benign
and cancer vs. healthy groups.
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